Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Trial of Individualised Care Versus Standard Care for Breast Cancer Patients at High Risk for Chemotherapy Induced Nausea and Vomiting. The ILIAD Study

NCT02861859 is registered in ClinicalTrials.gov with Ottawa Hospital Research Institute as lead sponsor.

NCT NCT02861859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02861859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Trial of Individualised Care Versus Standard Care for Breast Cancer Patients at High Risk for Chemotherapy Induced Nausea and Vomiting. The ILIAD Study
Lead sponsor
Ottawa Hospital Research Institute
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2016
Completion date
December 23, 2019
Enrollment
221 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer